123 reports of this reaction
1.9% of all AMLODIPINE AND ATORVASTATIN reports
#11 most reported adverse reaction
ASTHENIA is the #11 most commonly reported adverse reaction for AMLODIPINE AND ATORVASTATIN, manufactured by Pfizer Laboratories Div Pfizer Inc. There are 123 FDA adverse event reports linking AMLODIPINE AND ATORVASTATIN to ASTHENIA. This represents approximately 1.9% of all 6,537 adverse event reports for this drug.
Patients taking AMLODIPINE AND ATORVASTATIN who experience asthenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ASTHENIA is a less commonly reported adverse event for AMLODIPINE AND ATORVASTATIN, but still significant enough to appear in the safety profile.
In addition to asthenia, the following adverse reactions have been reported for AMLODIPINE AND ATORVASTATIN:
The following drugs have also been linked to asthenia in FDA adverse event reports:
ASTHENIA has been reported as an adverse event in 123 FDA reports for AMLODIPINE AND ATORVASTATIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
ASTHENIA accounts for approximately 1.9% of all adverse event reports for AMLODIPINE AND ATORVASTATIN, making it a notable side effect.
If you experience asthenia while taking AMLODIPINE AND ATORVASTATIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.